There are 2 alcohol/food interactions with metformin / repaglinide. Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.

In addition, metformin should generally be avoided in alcoholics and patients with clinical or laboratory evidence of hepatic disease, since alcohol potentiates the effects of metformin on lactate metabolism and impaired hepatic function may significantly limit the ability to clear lactate.

Applies to: Diabetes Type 1, Diabetic KetoacidosisThe use of meglitinides is contraindicated in patients with type I diabetes or for the treatment of diabetic ketoacidosis, with or without coma.Major Potential Hazard, High plausibility.

Select one or more newsletters to continue. metformin and repaglinide is not for treating type 1 diabetes. Higher serum drug levels, in addition to diminished gluconeogenic capacity secondary to hepatic insufficiency, may increase the potential for severe hypoglycemic episodes.

Metformin / repaglinide alcohol/food interactions. If lactic acidosis is diagnosed, prompt supportive measures and hemodialysis are recommended.Major Potential Hazard, Moderate plausibility. Major Food Interaction.

Although the decrease is generally well-tolerated and rarely associated with clinical manifestations such as megaloblastic anemia, caution may be warranted when metformin therapy is administered in patients with preexisting B12 deficiency. Major Potential Hazard, Moderate plausibility. Immediate medical attention is necessary if these symptoms occur, and metformin therapy withheld until the situation can be clarified. Applies to: Cardiovascular Disease, Cardiovascular DiseaseThe use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin. Select one or more newsletters to continue. Available for Android and iOS devices. WebMD provides information about interactions between Repaglinide-Metformin Oral and repaglinide-gemfibrozil. Applies to: Adrenal Insufficiency, Malnourished, Autonomic Neuropathy, Panhypopituitarism, Anorexia/Feeding Problems, Adrenal Insufficiency, Malnourished, Panhypopituitarism, Autonomic Neuropathy, Anorexia/Feeding ProblemsHypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents. Metformin and repaglinide is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes.

Therapy with repaglinide should be administered cautiously in patients with liver disease.

Patients with impaired liver function may be exposed to higher concentrations of repaglinide and its associated metabolites.

However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.Moderate Potential Hazard, Moderate plausibility. Applies to: Liver DiseaseRepaglinide is almost completely metabolized in the liver to pharmacologically inactive substances. We comply with the HONcode standard for trustworthy health information - Patients with these conditions may be at increased risk for the development of lactic acidosis, which is a rare but serious metabolic complication associated with metformin accumulation in plasma usually at levels exceeding 5 mcg/mL. A decrease to subnormal levels of previously normal serum B12 levels has been reported in approximately 7% of patients treated with metformin during controlled clinical trials. In addition, alcohol may cause … This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.

Table 3: Clinically Important Drug Interactions with Repaglinide and Metformin Hydrochloride Tablets; Carbonic Anhydrase Inhibitors: Clinical Impact: Carbonic anhydrase inhibitors frequently causes a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.Moderate Potential Hazard, Moderate plausibility. METFORMINE ET REPAGLINIDE : liste des médicaments suivant la Classification Anatomique, Thérapeutique et Chimique Concomitant use of these drugs with repaglinide and … Applies to: Renal Dysfunction, Liver Disease, Congestive Heart Failure, Dehydration, Shock, Myocardial Infarction, Asphyxia, Acidosis, Diarrhea, Vomiting, Anemia, AlcoholismThe use of metformin is contraindicated in patients with renal dysfunction (serum creatinine >= 1.5 mg/dL in males and 1.4 mg/dL in females, or above the upper limit of normal for age); congestive heart failure requiring pharmacologic treatment (especially unstable or acute CHF where there is risk of hypoperfusion and hypoxemia); and any condition associated with hypoxemia (e.g., severe anemia, myocardial infarction, asphyxia, shock), dehydration (e.g., severe diarrhea or vomiting), or sepsis.